Daily Stock Analysis, IMNP, Immune Pharmaceuticals Inc, priceseries

Immune Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.00
Close
0.00
High
0.01
Low
0.00
Previous Close
0.00
Daily Price Gain
0.00
YTD High
0.02
YTD High Date
Jan 16, 2019
YTD Low
0.00
YTD Low Date
Jan 3, 2019
YTD Price Change
-0.01
YTD Gain
-68.00%
52 Week High
0.39
52 Week High Date
Apr 16, 2018
52 Week Low
0.00
52 Week Low Date
Jan 3, 2019
52 Week Price Change
-0.34
52 Week Gain
-99.06%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 10. 2017
1.43
Oct 18. 2017
1.53
6 Trading Days
7.12%
Link
Company Information
Stock Symbol
IMNP
Exchange
NasdaqCM
Company URL
http://http://www.immunepharmaceuticals.com
Company Phone
646-440-9310
CEO
Daniel G. Teper
Headquarters
New York
Business Address
430 EAST 29TH STREET, SUITE 940, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001208261
About

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas.

Description

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The company's lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing NanoCyclo, a topical nanocapsule formulation of cyclosporine, for the treatment of psoriasis and atopic dermatitis; Ceplene, a small molecule, which has completed Phase III clinical trials targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies; Azixa, a Phase II clinical trial novel microtubular destabilizer that functions as a vascular disruption agent; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is in Phase II clinical trials for the treatment of patients with solid tumors. The company's products also include NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; novel technology platform for the construction of bispecific antibodies for immunotherapies; and AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies. It has license, and other collaborative research and development arrangements with BioNanoSim Ltd.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; Atlante Biotech SAS; Shire Biochem, Inc.; Lonza Sales AG; MabLife SAS; iCo Therapeutics Inc.; Dalhousie University; and Endo Pharmaceuticals Inc. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in New York, New York.